REDucing Hot FLASHes in Women Using Endocrine Therapy.
Status:
Not yet recruiting
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
The goal of this randomized intrapatient cross-over study is to assess the efficacy of
oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after
breast cancer.
The objectives it aims to answer are:
- To assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women
using endocrine therapy after breast cancer
- To assess side effects of oxybutynin versus venlafaxine.
- To assess the personal preference of women for oxybutynin versus venlafaxine in reducing
hot flashes.
- To assess quality of life of women when reducing hot flashes in women using endocrine
therapy after breast cancer.
Participants will fill-out a patient diary during 15 weeks total on a daily basis and receive
an (online) questionnaire three times total.
Researchers will compare two groups (venlafaxine group versus oxubutynine group) to assess
its efficacy concerning hot flashes.